1
Jaswant S Gidda, John M Schaus: Isoxazole derivatives for the treatment of irritable bowel syndrome. Eli Lilly and Company, Douglas J Taylor, July 18, 1995: US05434174 (22 worldwide citation)

Methods of treating Irritable Bowel Syndrome (IBS) using a series of isoxazole derivatives that have both 5-HT1A agonist and M1 muscarinic activities, and formulations adapted for the treatment of IBS comprising those derivatives.


2
Jaswant S Gidda, Herbert A Kirst, David W Robertson: Method for treating gastrointestinal disorders. Eli Lilly and Company, Nancy J Harrison, Leroy Whitaker, April 24, 1990: US04920102 (17 worldwide citation)

Novel ring-contracted macrolides which enhance gastrointestinal motility and novel methods and compositions for treating gtastrointestinal disorders in animals with these macrolides and with certain other previously known ring-contracted macrolides are provided.


3
Jaswant S Gidda, John M Schaus: Method of inhibiting gastric acid secretion. Eli Lilly and Company, John C Demeter, Leroy Whitaker, March 17, 1992: US05096908 (15 worldwide citation)

The present invention provides a method of inhibiting gastric acid secretion in mammals by administering a 5-HT1A agonist compound or a pharmaceutically acceptable salt thereof.


4
Jaswant S Gidda, Jill A Panetta, Michael L Phillips: Method of treating inflammatory bowel disease. Eli Lilly and Company, Douglas J Taylor, Leroy Whitaker, June 1, 1993: US05216002 (12 worldwide citation)

Provided is a method of treating inflammatory bowel disease in mammals utilizing certain benzyl-substituted rhodanine derivatives. Also provided are novel benzyl-substituted rhodanine derivatives and pharmaceutical compositions thereof, as well as a novel process for selectively isolating in substan ...


5
James E Audia, Marlene L Cohen, Jaswant S Gidda, David L G Nelson: Method for treating 5HT.sub.2B receptor related conditions. Eli Lilly and Company, MaCharri Vorndran Jones, David E Boone, November 18, 1997: US05688807 (11 worldwide citation)

The present invention provides methods for binding a 5-HT.sub.2B receptor in mammals using a both known and novel compounds. Further, the invention provides a method for treating or preventing 5-HT.sub.2B related conditions. Finally, the invention provides an article of manufacture.


6
Jaswant S Gidda, John M Schaus: Method of inhibiting gastric acid secretion with 2-phenylcyclopropylamines. Eli Lilly and Company, John C Demeter, August 23, 1994: US05340838 (7 worldwide citation)

The present invention provides a method of inhibiting gastric acid secretion in mammals by administering a 5-HT1A agonist compound or a pharmaceutically acceptable salt thereof.


7
Jaswant S Gidda, John M Schaus: Method of inhibiting gastric acid secretion with n-arylpiperazines. Eli Lilly and Company, John C Demeter, Leroy Whitaker, November 2, 1993: US05258379 (5 worldwide citation)

The present invention provides a method of inhibiting gastric acid secretion in mammals by administering a 5-HT1A agonist compound or a pharmaceutically acceptable salt thereof.


8
Jaswant S Gidda, John M Schaus: Method of inhibiting gastric acid secretion with benzodioxanes. Eli Lilly and Company, John C Demeter, Leroy Whitaker, October 27, 1992: US05158956 (5 worldwide citation)

The present invention provides a method of inhibiting gastric acid secretion in mammals by administering a 5-HT1A agonist compound or a pharmaceutically acceptable salt thereof.


9
James E Audia, Marlene Cohen, Jaswant S Gidda, David L Nelson: Method for treating 5-HT.sub.2B receptor related conditions. Eli Lilly and Company, MaCharri Vorndran Jones, David E Boone, January 6, 1998: US05705519 (4 worldwide citation)

The present invention provides methods for binding a 5-HT.sub.2B receptor in mammals using a both known and novel compounds. Further, the invention provides a method for treating or preventing 5-HT.sub.2B related conditions. Finally, the invention provides an article of manufacture.


10
James E Audia, Marlene L Cohen, Jaswant S Gidda, David L G Nelson: Naphthylpiperazinyl compounds useful for treating 5HT.sub.2B receptor mediated conditions. Eli Lilly and Company, Arleen Palmberg, David E Boone, MaCharri R Vorndran Jones, April 7, 1998: US05736544 (4 worldwide citation)

The present invention provides methods for binding a 5-HT.sub.2B receptor in mammals using both known and novel compounds. Further, the invention provides a method for treating or preventing 5-HT.sub.2B related conditions. Finally, the invention provides an article of manufacture.



Click the thumbnails below to visualize the patent trend.